Navigation Links
Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
Date:3/7/2013

BALTIMORE, March 7, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, today announced a number of developments that will support its expanding business.  The company licensed exclusive rights to Digital Karyotyping (DK), an important genome-mapping technology developed by the company's founders at Johns Hopkins University.  PGDx also announced that it is expanding into new facilities and has made a number of key hires, including Genzyme Oncology executive Antony Newton as Chief Commercial Officer.

PGDx's co-founders include Chief Scientific Officer Dr. Victor Velculescu and Chief Medical Officer Dr. Luis Diaz , international leaders in cancer genetics and faculty members at the Johns Hopkins University School of Medicine, who were the first to perform genome-wide sequence analyses of human cancer.  They and colleagues at Johns Hopkins, including Dr. Bert Vogelstein , a recent recipient of the Breakthrough Prize in Life Sciences for his work in colon cancer, established the company in response to requests from cancer researchers and clinicians for commercial access to their specialized genome-mapping services and analyses.  PGDx has licensed rights from Johns Hopkins to proprietary methods based on next-generation sequencing, patented approaches to genetic analysis and proprietary data algorithms, and its scientists have deep expertise in the practical application of these technologies to the study of cancer genomics. 

"At PGDx, we are fortunate to be able to bring the latest advances in cancer genomics such as Digital Karyotyping to cancer researchers and clinicians around the globe," said Antony Newton . "This is an exciting time for cancer genomics, and we expect to be announcing a number of collaborations and partnerships in the coming months as we bring our advanced capabilities to the many researchers and drug developers who are rapidly advancing the field." 

Newton added, "We also are using our CLIA-certified laboratory and our years of genomic know-how to provide information on tumor-specific mutations to cancer patients and their physicians.  As the utility of cancer genomics evolves, we are considering a number of options for expanding our ability to serve the growing demand for patient-specific analyses that can help inform treatment decisions."

As part of its services, PGDx employs cancer exome analysis, an approach the company pioneered, to capture and selectively analyze the coding regions of the genome, enabling the comprehensive and reliable genome-wide identification of cancer-related mutations in all of the approximately 20,000 relevant genes.  PGDx also provides in-depth computational analyses based on its proprietary methodologies to differentiate between unimportant and cancer-associated mutations.  

The patented DK technology enables quantitative analysis of DNA copy number at high resolution with exceptional sensitivity.  This method can identify large chromosomal changes in human cancer cells, along with amplifications and deletions, including those in regions not previously known to have been altered.  DK has enabled a number of landmark discoveries in human cancer, such as identification of gene amplification of the therapeutically targetable OTX2 gene in medulloblastoma, detection of thymidylate synthase amplification as a mechanism of chemotherapy resistance in colorectal cancer and comprehensive copy number analyses in large-scale cancer genome analyses.  The method can also be applied to other conditions, including analyses of chromosomal abnormalities in hereditary disorders.  Digital Karotyping complements other technologies licensed from Hopkins, including the CHASM computational method for identifying cancer-related mutations, which are being applied to both research and diagnostic applications.

Under the terms of its agreement with Johns Hopkins, PGDx has the right to sub-license the DK technology to third parties.

Mr. Newton was recently recruited to PGDx after a 19-year career at Genzyme Corporation, where he held a number of roles in marketing, commercial development and drug development.  He was most recently Vice President in the Oncology Division.

PGDx, which was originally located in the Johns Hopkins Science and Technology Park, has moved into larger laboratory and office facilities along the Inner Harbor area of Baltimore.

For more information on PGDx, visit: www.personalgenome.com/.

About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced genome-mapping services and analyses to oncology researchers, clinicians and patients. The company was founded in 2010 by international leaders in cancer genetics at Johns Hopkins University.  PGDx conducts patient-specific analyses aimed at identifying the unique genomic alterations in tumors and linking them to the underlying biology.  PGDx employs cancer exome analysis, which enables comprehensive and reliable genome-wide identification of cancer-related mutations. The company's proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics.  PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians.  For more information, visit www.personalgenome.com.

 Contacts: Corporate

MediaPersonal Genome Diagnostics

BLL Partners, LLC Antony Newton

Barbara Lindheim Chief Commercial Officer

212 584-2276410-849-9189

blindheim@bllbiopartners.com anewton@personalgenome.com  


'/>"/>
SOURCE Personal Genome Diagnostics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
2. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
3. Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
4. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
5. Ohio State Hosting International Personalized Health Care Leaders
6. UPMC Invests in Intelligent Infrastructure with IBM to Support Vision of Personalized Medicine
7. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
8. 23andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service®
9. CNIO researchers take part in the most comprehensive personalized medicine study performed to date
10. Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference
11. New Study Building Framework to Bring Personalized Medicine to the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):